Can you stay on 2.5mg Mounjaro long-term?

Why the evidence was built around doses above 2.5mg

The SURMOUNT-1 trial followed adults with obesity over 72 weeks and found average body-weight reductions of around 20–21% at the highest dose studied. The 2.5mg starting dose wasn't tested as a therapeutic endpoint in that programme; its role was to minimise gastrointestinal side effects in the weeks after starting. That design choice reflects something practical: nausea, vomiting and digestive discomfort are most noticeable when tirzepatide is new to your system, and a lower entry point gives the body time to adapt before exposure increases.

This matters because some people read the 2.5mg figure and assume it means the medicine isn't working yet. That's partly true by design. The appetite-regulating and metabolic effects of tirzepatide become more pronounced as the dose rises, which is why the licensed schedule steps upward roughly every four weeks. If you're on 2.5mg and wondering whether you should already be losing weight, the honest answer is: a little, possibly, but the bigger response comes later. If you want a fuller picture of what this dose can and cannot do, our page on whether staying on 2.5mg of Mounjaro is a viable long-term option goes into the evidence in detail. You can read more about what the 5mg dose looks like in practice if you're approaching your first potential step up.

None of this means you're obliged to rush. The point is simply that the evidence base for this medicine was assembled with dose escalation in mind, so the decision to stay at any particular dose should be a conscious clinical one, not a default.

When staying at 2.5mg (at least for now) is the right call

There are entirely legitimate reasons why a prescriber might advise you to hold at 2.5mg rather than move to 5mg on the standard four-week schedule. The most common is that side effects haven't yet settled. If nausea is still noticeable, if your digestion is disrupted, or if fatigue has been significant, titrating before your body has adjusted tends to compound those effects rather than resolve them. Staying put is not a failure; it's sensible dose management.

Some people also start Mounjaro alongside another medication or health condition that needs monitoring before a dose change. Prescribers may want to see a few weeks of stable blood pressure readings, glucose levels, or weight trend data before making a move. The broader question of staying on a low dose of Mounjaro covers this in more detail for anyone weighing up their options across the first few months.

What a prescriber would typically be cautious about is staying at 2.5mg indefinitely without a clinical reason. If your body has fully adjusted, side effects have cleared, and weight loss has plateaued, remaining at the starter dose is unlikely to deliver the results the treatment is capable of. The conversation with your prescribing team is the right place to make that call, not a decision made unilaterally based on how things feel week to week.

Side effects at 2.5mg, and whether increasing will make them worse

It's understandable to feel cautious here. If the first weeks on 2.5mg brought nausea or stomach discomfort, the prospect of increasing the dose can feel like agreeing to more of the same. That's a concern our prescribers hear regularly, and it deserves a straight answer.

Gastrointestinal side effects with tirzepatide are most prominent in the early weeks and after each dose increase, but they typically settle within days to two weeks as the body adapts. The pattern across the SURMOUNT trial programme showed that most participants experienced their worst GI symptoms early on and that these reduced over time, even as doses moved upward. The 2.5mg entry point exists precisely to make that initial adjustment as manageable as possible.

Moving to 5mg does mean a brief period of potential re-adjustment, but for most people this is milder than the initial experience. If you are concerned, that's a conversation worth having before any increase. You can also read about dosing timing and what's sometimes called the 'golden dose', the point at which many people find their response settles into a more comfortable pattern. Knowing what to expect makes the early weeks feel a lot more manageable.

What happens in practice: having the conversation with your prescriber

The most important thing to take from this page is straightforward: if you want to stay at 2.5mg, say so, and explain why. A good prescribing team will work with you rather than apply the titration schedule as though it's mandatory. If you're tolerating the starter dose well but feel anxious about moving up, that's a legitimate clinical input, not an awkward request.

At the same time, it's worth knowing what your prescriber will be looking for. They'll typically want to understand whether side effects are the driver, whether there are other health factors at play, and whether any weight-loss response has been seen. If none of those factors point to staying put, they may gently push for a step up, not because the schedule says so, but because the evidence suggests it's where the medicine does more of its work. A similar question arises later in treatment, and our page on whether staying on 7.5mg of Mounjaro is the right choice is worth reading if you're thinking ahead to that stage.

If you're considering Mounjaro for the first time and want to understand the full treatment landscape, our Mounjaro overview page covers everything from how the medicine is licensed to how private treatment works in the UK. And if you'd like to discuss your specific situation with a prescriber directly, the team at our weight-loss treatments page is the place to start, every consultation is reviewed by a GPhC-registered prescriber, not an automated system. For background on how we approach clinical oversight, our clinical team profile sets out who reviews the consultations we receive.